87.21MMarket Cap-2.71P/E (TTM)
2.100High1.970Low4.74KVolume2.100Open2.060Pre Close9.65KTurnover0.02%Turnover RatioLossP/E (Static)44.27MShares4.38052wk High1.54P/B39.61MFloat Cap1.74052wk Low--Dividend TTM20.11MShs Float31.830Historical High--Div YieldTTM6.31%Amplitude0.900Historical Low2.034Avg Price1Lot Size
Adagene Stock Forum
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.
Two posters will be presented on November 9:
Abstract 506: Comparing the ...
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Rhea-AI Impact(Moderate)Rhea-AI Sentiment(Very Positive)TagsRhea-AI SummaryPositiveDoubled confirmed partial responses to four in MSS CRC patients without liver and peritoneal metastases24% overall response rate (ORR) with...
No comment yet